Some “conventional” lutetium‐177 formulations are already available for the treatment, for example, of prostate‐specific membrane antigen (PSMA)‐positive metastatic castration‐resistant prostate cancer (177Lu‐PSMA‐617) or somatostatin receptor‐positive gastroenteropancreatic neuroendocrine tumors (177Lu‐DOTATATE). Here, FOLH1 is linked to neuroendocrine neoplasm.